SRSA Stock Overview
Sarissa Capital Acquisition Corp. does not have significant operations.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Sarissa Capital Acquisition Corp. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$10.05 |
| 52 Week High | US$10.80 |
| 52 Week Low | US$9.72 |
| Beta | 0 |
| 1 Month Change | 0.50% |
| 3 Month Change | 1.01% |
| 1 Year Change | 2.03% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -5.37% |
Recent News & Updates
Recent updates
Shareholder Returns
| SRSA | US Capital Markets | US Market | |
|---|---|---|---|
| 7D | 0.1% | 3.3% | 3.3% |
| 1Y | 2.0% | 35.5% | 25.0% |
Return vs Industry: SRSA underperformed the US Capital Markets industry which returned 8% over the past year.
Return vs Market: SRSA underperformed the US Market which returned 14.1% over the past year.
Price Volatility
| SRSA volatility | |
|---|---|
| SRSA Average Weekly Movement | 0.2% |
| Capital Markets Industry Average Movement | 3.5% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: SRSA has not had significant price volatility in the past 3 months.
Volatility Over Time: SRSA's weekly volatility (0%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2020 | n/a | Alex Denner | n/a |
Sarissa Capital Acquisition Corp. does not have significant operations. The company focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. It intends to identify and acquire a business, which focuses on the healthcare and biopharmaceutical industry.
Sarissa Capital Acquisition Corp. Fundamentals Summary
| SRSA fundamental statistics | |
|---|---|
| Market cap | US$251.25m |
| Earnings (TTM) | US$12.65m |
| Revenue (TTM) | n/a |
19.9x
P/E Ratio0.0x
P/S RatioIs SRSA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SRSA income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | -US$12.65m |
| Earnings | US$12.65m |
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.51 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did SRSA perform over the long term?
See historical performance and comparison